You are here
P&T December 2013
In a retrospective study to assess the use of antithrombin concentrates, the authors judged the plasma-derived product (Thrombate III) to be more cost-effective than the recombinant human form (ATryn) for patients with hereditary antithrombin deficiency.
Calculating the Dose of Subcutaneous Immunoglobulin for Primary Immunodeficiency Disease in Patients Switched From Intravenous to Subcutaneous Immunoglobulin Without the Use of a Dose-Adjustment Coefficient
Intravenous immunoglobulin (IVIG), a standard therapy for immune deficiency disorders, is not appropriate for all patients. As a result, a subcutaneous form (SCIG) has emerged as an alternative. The authors propose a tailored dosing approach for SCIG.
Rheumatology topics included therapies for rheumatoid arthritis, psoriatic arthritis, and Behçet’s syndrome. At the TCT meeting, researchers examined the effects of pharmacological strategies for myocardial infarction, along with platelet function testing as a guide to antiplatelet therapy.
Experts Comment on Recent Developments
Part 1 covers promising biologics that aim to promote safety and efficacy in treating psoriatic lesions. Part 2 addresses the problem of nonadherence to treatment.
New FDA rules on medical devices shouldn’t be a burden for hospitals that can scan unique device identifiers.
Avoiding pitfalls when conducting a root cause analysis
Glucarpidase (Voraxaze) for methotrexate toxicity
Duavee, an oral contraceptive; riociguat (Adempas) for two types of pulmonary hypertension; and macitentan (Opsumit) for pulmonary arterial hypertension
FDA approvals, drug indications, and updates